drugset / Trial / NCT05835479
Rezafungin for Treatment of Pneumocystis Pneumonia in HIV Adults
RandomizedParallel-groupOpen-labelTreatment
Summary
This study aims to generate clinical data on the efficacy, safety, and tolerability of rezafungin combined with 7 days of co-trimoxazole for treatment of Pneumocystis pneumonia (PCP) in adults living with human immunodeficiency virus (HIV), which would expand the knowledge of clinical use of rezafungin.
Timeline
- Start
- 2023-11-14
- Primary completion
- 2025-05
- Completion
- 2025-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rezafungin | Other / unclassified | 200 mg | Intravenous |
| Comparator | Sulfamethoxazole | Small molecule | 37.5 mg/kg | Oral |
| Comparator | Sulfamethoxazole | Small molecule | 50 mg/kg | Oral |
| Comparator | Sulfamethoxazole | Small molecule | 75 mg/kg | Oral |
| Comparator | Sulfamethoxazole | Small molecule | 100 mg/kg | Oral |
| Comparator | Trimethoprim | Small molecule | 7.5 mg/kg | Oral |
| Comparator | Trimethoprim | Small molecule | 10 mg/kg | Oral |
| Comparator | Trimethoprim | Small molecule | 15 mg/kg | Oral |
| Comparator | Trimethoprim | Small molecule | 20 mg/kg | Oral |